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Abstract: The osmotic release oral system (OROS) methylphenidate formulation is a 
prolonged-release medication for the treatment of attention-deficit/hyperactivity disorder 
(ADHD) in children, adolescents, and adults. We conducted a seven-week open-label extension of 
a double-blind study to assess the safety and tolerability of OROS methylphenidate in a flexible 
dose regimen (18–90 mg daily) for the treatment of adults diagnosed with ADHD (N = 370). 
Medication was adjusted to optimize efficacy and tolerability for each patient. Adverse events, 
vital signs, and laboratory parameters were assessed. Most patients (337; 91%) completed 
the seven-week treatment and the final dispensed dose was 18 mg (8%), 36 mg (29%), 54 mg 
(34%), 72 mg (20%), or 90 mg (9%). Adverse events were reported in 253 (68%) patients and 
most were mild or moderate in severity; most frequently reported included headache (17%), 
decreased appetite (13%), and insomnia (11%). Adverse events were rarely serious (1%; 
2/370). Small mean increases in systolic and diastolic blood pressure (both 2.4 mmHg) and 
pulse (3.2 bpm) were observed. Body weight decreased slightly (-1.5 kg). The results provide 
additional support for the safety and tolerability of prolonged-release OROS methylphenidate 
in a flexible dose regimen (18–90 mg/day) for the treatment of adults with ADHD.
Keywords: attention deficit hyperactivity disorder, ADHD, adult, methylphenidate, safety
Introduction
There is increasing recognition of the need for treatment of attention-deficit/hyperactivity 
disorder (ADHD) in adults, with mounting evidence that symptoms persist beyond 
childhood.1 Adults show similar responsiveness to methylphenidate treatment for 
ADHD as seen in children.2–12 Recent literature reviews of the safety of methylphenidate 
in the treatment of ADHD in adults and other conditions concluded that the medication 
is effective and well tolerated.13,14 With growing support for methylphenidate treatment 
of ADHD in adults, the safety and tolerability of methylphenidate formulations and 
regimens in treatment of ADHD in adults merit further investigation.15–17
The osmotic release oral system (OROS) methylphenidate formulation is designed 
to deliver methylphenidate in a controlled manner for approximately 12 hours, 
thereby allowing extended coverage of symptoms during the day. This long-acting 
formulation, designed for once-a-day administration, was shown to be an effective 
and safe treatment of ADHD in children and adolescents,18–20 and more recently in 
adults.21–24 This prolonged-release medication (Concerta®; McNeil Pediatrics Division 
of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ, USA) is approved for 
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the treatment of ADHD in children and adolescents in various 
countries, and for the treatment of ADHD in adults in the 
United States and Canada.
Recently, Medori and colleagues23 reported findings 
from a double-blind, placebo-controlled trial in which three 
fixed doses of OROS methylphenidate were administered 
once daily over five weeks for the treatment of ADHD 
in 401 adults. The three dosages of medication (18, 36, 
72 mg) were each an effective treatment of ADHD in 
adults, with a safety and tolerability profile consistent with 
methylphenidate use in children and adolescents. The trial 
included a subsequent open-label treatment phase to evaluate 
the safety of the medication under treatment conditions more 
consistent with actual clinical practice. In the open-label 
phase, patients received a flexible dose regimen of the medi-
cation (18–90 mg daily) to optimize efficacy and tolerability 
for each patient based on the investigators’ judgment of 
clinical response. Flexible dosing more closely parallels 
clinical practice than fixed dosing and therefore may provide 
additional clinically relevant findings.
We report the results of the seven-week open-label 
extension of the Medori and colleagues trial.23 Patients 
who completed the double-blind phase or discontinued 
study medication due to poor tolerability received a flexible 
dose regimen of the medication (18–90 mg daily) so as to 
optimize efficacy and tolerability for each patient based on 
the investigators’ judgment of clinical response. The primary 
purpose of the open-label phase was to evaluate the safety 
and tolerability of flexible dosages of OROS methylphenidate 
through assessments of adverse events, vital signs, clinical 
laboratory tests, and physical examination.
Methods
Background
Medori and colleagues reported a double-blind phase of a trial 
in which adults with ADHD (18–65 years) were randomly 
assigned to receive OROS methylphenidate (18, 36, or 
72 mg/day) or placebo for five weeks. Study procedures 
included administration of efficacy measures, monitoring 
of adverse events, clinical laboratory tests (hematology, 
biochemistry), vital signs (supine and standing blood pressure, 
pulse), and physical examination at baseline and at the end 
of weeks 1, 3, and 5, or at early withdrawal. Patients who 
completed the double-blind phase or discontinued the double 
blind phase of the study due to poor tolerability were eligible 
to participate in a seven-week open-label extension during 
which they received a flexible dose regimen of prolonged 
release (PR) OROS methylphenidate (18–90 mg/day) with 
adjustment to optimize efficacy and tolerability for each 
patient based on the investigators’ judgment of clinical 
response.
Of the original 401 patients enrolled in the double-blind 
trial, 370 (92%) continued to the open-label phase of the study. 
Of these 370 patients, 363 (98.1%) had previously completed 
the double-blind study and seven (1.9%) had not due to lack 
of efficacy (five patients) or adverse events (two patients). The 
discontinuations due to adverse events included one patient in 
the 36 mg/day treatment group described as having ongoing 
delusion of reference that resolved during the treatment 
interruption, and a second patient in the 72 mg/day group 
who reported anxiety, psychomotor agitation, disturbance 
in attention, and irritability.
The trial was conducted at 51 investigator sites in 
13 European countries (listed in Acknowledgments) from 
April 2005 to June 2006. Ethics Committee approval was 
obtained and patients gave informed consent to participate.
Patients
The trial included adult men and women with a diagnosis 
of ADHD according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV),25 and confirmed by the Conners’ Adult ADHD 
Diagnostic Interview for DSM-IV (CAADID).26 Other 
requirements for inclusion were: age 18–65 years; chronic 
course of ADHD symptomatology from childhood to 
adulthood with some symptoms present before 7 years of 
age, as determined by investigators following the CAADID 
interview; and total score of 24 at screening on Conners’ 
Adult ADHD Rating Scale (CAARS; Investigator-
rated).26 The Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I) was used to evaluate the presence 
of other comorbidities.27 The diagnosis of ADHD was not 
made if symptoms were better accounted for by another 
psychiatric disorder (eg, mood, anxiety, psychotic, person-
ality disorder). Patients were excluded if: the investigator 
judged they (or their child) had a history of poor response 
or intolerance to methylphenidate; diagnosed with any 
current clinically unstable psychiatric condition (eg, acute 
mood disorder, bipolar disorder, acute obsessive-compulsive 
disorder), as determined by the investigator; or diagnosed 
with substance use disorder (abuse/dependence) according to 
DSM-IV criteria within the last six months. Other exclusion 
criteria included family history of schizophrenia or affective 
psychosis; serious illnesses (eg, hepatic or renal insufficiency, 
significant cardiac, gastrointestinal, psychiatric, or metabolic 
disturbances); hyperthyroidism, myocardial infarction, or 
Neuropsychiatric Disease and Treatment 2009:5 459
Safety of OROS methylphenidate in adults with ADHDDovepress
submit your manuscript | www.dovepress.com
Dovepress 
stroke within six months of screening; and history of seizures, 
glaucoma, or uncontrolled hypertension.
Patients were eligible to continue in the seven-week 
open-label extension if they still met the initial inclusion 
and exclusion criteria (except for criteria concerning prior 
treatment with methylphenidate and CAARS score 24) 
and they completed the double-blind phase or discontinued 
treatment after a minimum of seven treatment days. Patients 
who had received a stable dose of an antidepressant (except 
MAO inhibitors) for at least three months prior to screening 
could continue this treatment at the same dose during the 
open-label phase. The continued use of antidepressants 
(eg, citalopram, escitalopram) by only a small number of 
patients (3.5%) was not expected to influence the assessment 
of OROS methylphenidate treatment. Patients treated at 
German or Spanish centers who discontinued the double-blind 
phase due to poor tolerability were not permitted to enter the 
open-label phase due to Ethics Committee requirements.
Procedure
Patients who entered the open-label extension received 
flexible dosages of OROS methylphenidate (18, 36, 54, 
72 or 90 mg/day) for seven weeks. Patients began with 
36 mg/day and were titrated to the most appropriate OROS 
methylphenidate dose to preserve the blinding of the 
treatment received in the double-blind phase. The 36 mg/day 
dosage was considered an appropriate starting dose to 
maintain some efficacy for patients who were receiving 
72 mg/day OROS methylphenidate during the double-blind 
phase, while avoiding tolerability issues for those patients 
who received 18 mg/day or placebo during the double-blind 
phase. Patients at German centers began with 18 mg/day due 
to Ethics Committee requirements. Titration of dosing was 
based on clinical observations of response and tolerability. 
The dosage could be increased by 18 mg increments to 
improve efficacy, to a maximum of 90 mg/day, or decreased 
by 18 mg increments to improve tolerability. Investigators 
were encouraged to wait at least seven days to change the 
dosage.
The final visit of the double-blind phase was considered 
the baseline visit for the open-label phase, and included 
administration of efficacy measures, clinical laboratory tests 
(hematology, biochemistry), vital signs, physical examination, 
and confirmation that the patient met the required inclusion 
and exclusion criteria. Study visits during the open-label 
phase occurred at the end of weeks 1, 3, and 7 (or early 
termination); procedures included vital signs, concomitant 
medication review, adverse event monitoring, dispensing of 
study medication, and study drug accountability and dosing 
compliance, and the CAARS efficacy measure. The final 
visit also included clinical laboratory tests (hematology, 
biochemistry) and physical examination. Designated 
time intervals after first intake of medication was defined 
as week 1 (1–13 days), week 3 (14–31 days), or week 7 
(32 days) during the open label phase. A post-study visit 
occurred one week after the last dose of study medication.
Assessments
The safety and tolerability of OROS methylphenidate 
treatment were addressed via assessments of adverse 
events (using the Medical Dictionary for Regulatory 
Activities),a clinical laboratory tests, vital signs, and physical 
examination. A treatment-emergent adverse event was 
defined as any sign, symptom, syndrome, or new illness 
that appeared or worsened during the open-label phase, and 
included laboratory findings or results of other diagnostic 
procedures considered medically important. Adverse events 
were recorded throughout the open-label phase, along with 
action taken (none, dose reduced, drug stopped temporarily, 
drug stopped permanently). Based on standard definitions, 
the investigator judged the severity of an adverse event (mild, 
moderate, or serious) and relationship to the study drug 
(not related, doubtful, possible, probable, very likely). The 
evaluation of the safety data included all subjects who took 
at least one dose of study medication during the open-label 
phase. The incidence of adverse events was summarized 
overall and by daily dose over weeks 1, 3, and 7. Descriptive 
statistics were computed for each laboratory analyte, vital 
sign, and weight measurements.
An efficacy analysis evaluated the change in CAARS 
total score from end of double-blind treatment (baseline) at 
each visit (last observation carried forward) in patients who 
received at least one dose of medication and had at least one 
post-baseline efficacy measurement during the open-label 
phase. Within-group statistical testing for change from 
double-blind end point was performed using a two-sided 
paired t-test. All statistical analyses were performed using 
SAS (Version 8.02; SAS Institute, Cary, NC, USA).
Results
Patient disposition
The flow of patients from the double-blind phase through 
the open-label phase of the trial is presented in Figure 1. 
aMedDRA®: international medical terminology developed under the auspices 
of the International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH).
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Entered double-blind, n
Enrolled, n (%)
Daily dose on 
visit day 
Week 1, n (%) 
Week 3, n (%)
Week 7, n (%)
Five-week double-blind phase 
Randomized and treated (N = 401) 
Placebo or fixed-dose OROS methylphenidate 
18 mga
101
(27.3) 
18 mg/day
101
Placebo 
96
36 mg/day
102
72 mg/day 
102
24
(6.6)
21
(6.1)
Seven-week flexible-dose open-label phase  
Enrolled and administered OROS methylphenidate (N = 370) 
Allocated daily dose of 18 mg, 36 mg, 54 mg, 72 mg, 90 mg 
36 mg
237
(64.0)
133
(36.6)
82
(23.7)
54 mg
11
(3.0)
154
(42.4)
110
(31.8)
72 mg
1
(0.3)
33
(9.1)
65
(18.8)
90 mg
1
(0.3)
4
(1.1)
32
(9.2)
Otherb
19
(5.1)
15
(4.1)
36
(10.4) 
Total
370
(100) 
363
(98.1)
346
(93.5)
93 (97) 95 (94) 95 (93) 87 (85) 
Completed seven-week open-label treatment (n = 337; 91.1%) 
Figure 1 Flow of patients from the double-blind phase through the open-label phase of the trial.
Notes: aPatients at German centers began with 18 mg/day; bOther includes patients who took no drug on the visit day or did not have a visit during the time interval (week 1 
[1–13 days], week 3 [14–31 days], week 7 [32 days]).
Abbreviation: OROS, osmotic release oral system.
A total of 370 patients enrolled in the open-label phase and 
were administered study drug. Of these patients, 337 (91.1%) 
completed the seven-week treatment period. Eighteen (4.9%) 
patients permanently discontinued treatment due to one or 
more adverse events and 15 (4%) patients discontinued for 
other reasons (lost to follow-up [5], noncompliance [4], lack 
of efficacy [1], and other [5]).
Patients in the open-label phase did not differ in 
demographic and clinical characteristics from those 
randomized in the double-blind phase, which have been 
described elsewhere.23 For the 370 patients in the open-label 
phase, median age was 35 years (M = 34.3, SD = 10.29), 
median weight was 77 kg (M = 78.0, SD = 17.13), 54% were 
male, and 98% were Caucasian. Median age at diagnosis of 
ADHD was 32 years (range  1–63), with the majority (74%) 
having documented ADHD combined subtype as a child 
(adult diagnosis). Currently active and stable psychiatric 
comorbidities in the study population included mood and 
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anxiety disorders in 12% of patients and personality disorders 
in 1% of patients.
Dosage and exposure
Mean duration of exposure was 47.6 days (range 2–90), 
with a mean average daily dose (excluding no dose days) of 
47.5 mg, mean minimum dose of 29.4 mg, and mean maxi-
mum daily dose of 57.6 mg (Table 1). The mean daily dose 
at weeks 1, 3, and 7 was 36.4 mg, 49.2 mg, and 52.4 mg, 
respectively. The most frequently used daily dose was 36 mg 
at week 1 (64%), 54 mg at week 3 (42%), and 54 mg at week 
7 (32%). The 54 mg daily dose was most frequently admin-
istered as a last dose (34%) and maximum dose (36%). The 
other daily dosages, 18 mg, 36 mg, 72 mg and 90 mg, were 
administered as a last dose to 8%, 29%, 20%, and 9% of the 
patients, respectively.
Adverse events
Adverse events are summarized in Table 2 for the 
370 patients. Overall, 253 (68%) patients experienced at least 
one treatment-emergent adverse event. The most frequently 
reported adverse events were headache, decreased appetite, 
and insomnia, and the highest incidence was for the category 
nervous system disorders (35%), psychiatric disorders (23%), 
and gastrointestinal disorders (21%). The most frequently 
occurring adverse events considered by the investigator as 
at least possibly related to study medication by the investi-
gator were decreased appetite (12%), headache (9%), and 
insomnia (9%). The majority of the adverse events were 
mild or moderate in severity. Two patients experienced a 
serious adverse event during open-label treatment. No deaths 
occurred in this trial.
The incidence of adverse events by daily dose over 
weeks 1, 3, and 7 is provided in Table 3. The incidence (%) 
of adverse events decreased for all five dosages over the 
seven-week treatment period. The most frequently occurring 
adverse events recorded at the final treatment visit (week 7) 
according to the patient’s daily dose at this visit are presented 
in Table 4.
Serious adverse events
Two patients reported a serious adverse event during 
open-label treatment. A 40-year-old man started at a daily 
dose of 18 mg that was increased to 36 mg after one week, 
and 22 days later, he was admitted to the hospital due to acute 
psychological stress. Treatment was stopped 19 days after 
admission, the patient was discharged two days later, and 
acute psychological stress resolved five days later. The 
investigator assessed the event as moderate in severity and 
not related to study medication. A second man (age 46) 
reported a foreign body in the urethra, and after it was 
removed, the patient was considered recovered and was 
discharged from hospital. The investigator did not consider 
the adverse event related to study drug.
Two patients reported serious adverse events during the 
post-study period. Five days after her last dose of medication 
(54 mg daily), a 27-year-old woman experienced an increase 
in anxiety and was hospitalized in a psychiatric unit. Seven 
days later, the patient recovered from the event and was 
discharged from hospital. The investigator judged the event 
as severe and not related to trial medication. A 27-year-old 
man experienced temporal arteritis and severe headache 
six days after his last study medication (90 mg daily) and 
was hospitalized for less than 12 hours. The events lasted 
approximately two hours and were considered serious (ie, 
requiring hospitalization) and considered doubtfully drug 
related by the investigator.
Discontinuations due to adverse events
Seventeen (5%) patients permanently discontinued trial 
medication due to one or more adverse events. These 
adverse events included upper abdominal pain, decreased 
weight, decreased appetite, depressed mood and depression 
Table 1 Study medication administered during the open-label phase
Treatment summarya Descriptive statistic (N = 370)
Mean (SD) Median Range
Treatment duration (days) 47.6 (9.13) 49.0 2–90
Average daily dose (mg)b 47.5 (13.93) 46.4 18–82
Average daily dose (mg)c 46.5 (14.18) 46.3 15–82
Last dose (mg) 52.6 (19.29) 54.0 18–90
Maximum dose (mg) 57.6 (18.11) 54.0 18–108
Minimum dose (mg)d 29.4 (8.88) 36.0 18–54
Distribution of last dose and maximum dose, n (%)
Daily dose Last dose Maximum dose
18 mg 29 (7.9) 5 (1.4)
36 mg 108 (29.3) 96 (26.0)
54 mg 127 (34.4) 133 (36.0)
72 mg 73 (19.8) 93 (25.2)
90 mg 32 (8.7) 40 (10.8)
108 mg – 2 (0.5)e
Notes: aMedication data not available for one patient; bExcludes zero dose days; 
cIncludes zero dose days; dExcludes zero dose days; minimum dose was generally the 
starting dose; eTwo patients assigned to a 54 mg daily dose took a double dose for 
one day and two days, respectively.
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each reported by two patients. The onset of these adverse 
events occurred at different daily dosages, with three events 
at 18 mg, 13 at 36 mg, seven at 54 mg, and two at 72 mg. 
Patients recovered from these adverse events, except for a 
report of depressed mood in one patient and decreased weight 
in another patient. The daily dosage was 36 mg at the onset 
of these two adverse events. The investigators considered 
decreased weight as moderate and probably related to the 
trial medication, and depressed mood as mild and doubtfully 
related to the trial medication.
Laboratory values
Abnormal laboratory values were infrequently reported 
as adverse events. There were no discontinuations due to 
laboratory-related adverse events and none of these adverse 
events were reported as serious or severe, except for one 
patient with an abnormally increased creatine phosphokinase 
level. The event was considered not drug-related and resolved 
three weeks after completion of the study. There were no 
other clinically notable mean changes in laboratory values 
over time.
Cardiovascular-related effects
Small mean increases in systolic and diastolic blood 
pressure and pulse were observed during the open-label 
phase. The mean (SD) increase in blood pressure from the 
end of double-blind treatment to the end of open-label was 
2.4 (14.9) mmHg for systolic and 2.4 mmHg (9.5) diastolic 
(measured while patient was standing). The increase in 
standing pulse was 3.2 (14.4) beats per minute (bpm). These 
modest changes were not considered clinically significant.
Changes in blood pressure and pulse during open label 
treatment were evaluated for patients who received placebo 
versus OROS methylphenidate during the double-blind 
phase. In placebo-treated patients, mean (SD) blood 
pressure changed from 125.6 (16.6) to 128.2 (16.6) mmHg 
for systolic and from 80.3 (11.0) to 84.2 (10.6) mmHg for 
diastolic from the end of double-blind treatment to the end 
of open-label. The corresponding changes were similar in 
OROS methylphenidate-treated patients; 124.4 (14.3) to 
126.7 (15.5) mmHg and 80.5 (10.7) to 82.9 (10.6) mmHg. 
Pulse increased from 80.2 (13.3) to 87.4 (14.3) bpm in 
placebo-treated and 84.6 (14.3) to 87.4 (13.7) bpm in OROS 
methylphenidate-treated patients.
Clinically relevant criteria for elevated/increased systolic 
(140 mmHg) or diastolic (90 mmHg) blood pressure, 
or pulse (90 bpm) were predefined. The number (%) of 
patients who met these criteria at the last treatment visit 
(week 7) are presented by the patient’s daily dose at this 
Table 2 Adverse events during the open-label phase
Category Treated patients (N = 370) 
n (%)
Any serious adverse event 2 (1)
Discontinued due to adverse event 17 (5)
Any adverse event 253 (68)
Possibly related to trial medicationa 195 (53)
Adverse event 2% totalb
 Headache 62 (16.8)
 Decreased appetite 47 (12.7)
 Insomnia 41 (11.1)
 Nausea 26 (7.0)
 Nasopharyngitis 21 (5.7)
 Restlessness 19 (5.1)
 Initial insomnia 17 (4.6)
 Dry mouth 15 (4.1)
 Fatigue 15 (4.1)
 Dizziness 14 (3.8)
 Anxiety 13 (3.5)
 Palpitations 12 (3.2)
 Depressed mood 11 (3.0)
 Tachycardia 10 (2.7)
 Nervousness 10 (2.7)
 Influenza 9 (2.4)
 Hyperhidrosis 9 (2.4)
 Disturbance in attention 8 (2.2)
Notes: aIncludes relationship of ‘possibly’, ‘probably’, and ‘very likely’; bSummarized by 
preferred term according to Medical Dictionary for Regulatory Activities (MedDRA).
Table 3 Percent of patients who reported an adverse event by daily dose and treatment period
Treatment period Daily dosage of OROS methylphenidate (N = 370)
18 mg 36 mg 54 mg 72 mg 90 mg
Week 1 46% (46/101) 44% (104/237) 36% (4/11) 0% (0/1) 100% (1/1)
Week 3 38% (9/24) 30% (40/133) 49% (76/154) 49% (16/33) 0% (0/4)
Week 7 33% (7/21) 23% (19/82) 26% (29/110) 31% (20/65) 38% (12/32)
Notes: Numerator is number of patients reporting any adverse event; denominator is total number of patients in the same dosage and treatment week. Excludes patients 
who took no drug on the visit day for the treatment week or did not attend the visit day (see Figure 1).
Abbreviation: OROS, osmotic release oral system.
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visit in Table 5. For blood pressure and pulse, the percentage 
of patients who met these criteria appears similar across 
the lower three doses (18, 36, 54 mg), with a trend for a 
larger percentage at the higher two doses (72 and 90 mg). 
The percentage of patients who met these criteria before 
entering the open-label phase varied across their double-blind 
treatment group: systolic (13%–21%), diastolic (14%–25%), 
and pulse (22%–41%).
One patient discontinued trial medication due to raised 
blood pressure (systolic 125 mmHg and diastolic 90 mmHg), 
which the investigator assessed as moderate in severity 
and probably drug-related. A second patient discontinued 
trial medication due to worsening of high blood pressure 
and paraesthesia. High blood pressure was reported at 
baseline of the double-blind phase (systolic 142 mmHg 
and 94 diastolic mmHg) and increased at the time of 
discontinuation of the open-label phase (systolic 184 mmHg 
and diastolic 103 mmHg). The investigator assessed 
worsening of high blood pressure and paraesthesia feeling 
in right arm as moderate and mild in severity and very likely 
and possible related to study medication, respectively.
Tachycardia was reported as an adverse event in 10 patients 
(4%) and 12 patients (3%) experienced palpitations. One 
patient experienced tachycardia and discontinued trial 
medication (36 mg daily) because of this adverse event. The 
investigator considered the adverse event as mild in severity 
and probably drug-related.
Body weight
Decreased weight was reported as an adverse event for 
seven subjects. One patient discontinued study medication 
because of decreased weight; a second patient discontinued 
trial medication because of decreased weight and decreased 
appetite; and a third patient reported decreased appetite as 
reason for discontinuing trial medication, along with other 
adverse events. There was a small mean (SD) decrease in 
weight of -1.5 kg (2.29) over the seven-week treatment 
period.
Efficacy assessment
The primary efficacy measure during the open-label phase 
was the mean change in CAARS total score from the 
end of double-blind treatment, which was assessed using 
within-group two-sided paired t-tests. Patients who received 
placebo in the double-blind phase showed improvement 
with a significant mean decrease (M = -3.5, SD = 8.49) 
in CAARS total score after one week of treatment in the 
Table 4 Adverse events by daily dose at final treatment visit
Adverse event, n (%) Daily dosage of OROS methylphenidate 
(N = 370)
18 mg 36 mg 54 mg 72 mg 90 mg
Headache 2 (9.5) 2 (2.4) 4 (3.6) 5 (7.7) 1 (3.1)
Decreased appetite 0 0 1 (0.9) 1 (1.5) 2 (6.3)
Insomnia 1 (4.8) 1 (1.2) 4 (3.6) 1 (1.5) 1 (3.1)
Nausea 0 1 (1.2) 1 (0.9) 0 0
Nasopharyngitis 1 (4.8) 6 (7.3) 3 (2.7) 3 (4.6) 1 (3.1)
Restlessness 1 (4.8) 1 (1.2) 1 (0.9) 2 (3.1) 0
Dry mouth 1 (4.8) 0 0 0 1 (3.1)
Fatigue 0 1 (1.2) 0 0 0
Dizziness 1 (4.8) 0 0 1 (1.5) 0
Anxiety 1 (4.8) 2 (2.4) 0 0 0
Palpitations 1 (4.8) 1 (1.2) 0 1 (1.5) 0
Depressed mood 0 0 2 (1.8) 2 (3.1) 1 (3.1)
Tachycardia 0 1 (1.2) 1 (0.9) 1 (1.5) 0
Nervousness 1 (4.8) 0 0 0 0
Influenza 0 0 0 1 (1.5) 0
Disturbance in attention 0 0 0 1 (1.5) 1 (3.1)
Notes: Adverse events reported in 2% total patients (see Table 2); n = number of 
patients with a particular adverse event at week 7 visit; percentage denominator is total 
number of patients with the same dosage at final treatment week. Excludes patients 
who took no drug on the final visit day or did attend the visit (see Figure 1).
Abbreviation: OROS, osmotic release oral system.
Table 5 Patients who met clinically relevant criteria for cardiovascular-related measurements by daily dose at final treatment visit
Measurement, n (%) Daily dosage of OROS methylphenidate (N = 370)
18 mg  
n = 21
36 mg  
n = 82
54 mg  
n = 110
72 mg 
n = 65
90 mg  
n = 32
Systolic blood pressure 
(140 mmHg)
2 (9.5) 13 (15.9) 20 (18.2) 14 (21.5) 11 (34.4)
Diastolic blood pressure 
(90 mmHg)
6 (28.6) 23 (28.0) 25 (22.7) 22 (33.8) 12 (37.5)
Pulse  
(90 beats per minute)
7 (33.3) 29 (35.4) 37 (33.6) 32 (49.2) 16 (50.0)
Note: Measured while patient standing; n = number of patients who met criteria; percentage denominator is total number of patients with the same dosage at final treatment 
week. Excludes patients who took no drug on the visit day for the treatment week or did not attend the visit day (see Figure 1).
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open-label phase, and their total score further decreased 
at week 3 (M = -6.7, SD = 8.79) and week 7 (M = -8.5, 
SD = 9.65) (p values  0.001). Patients treated with OROS 
methylphenidate during double-blind phase showed a small 
improvement at week 1 (M = -0.6, SD = 7.96) and a larger 
significant decrease in their total score at week 3 (M = -4.3, 
SD = 8.21) and week 7 (M = -6.5, 9.31) (p values  0.001 
at week 3 and 7).
Discussion
This seven-week open-label, flexible dosage extension 
of a five-week double-blind, fixed dose study provided 
further support for the safety and tolerability of OROS 
methylphenidate in a flexible dose regimen (18–90 mg 
daily) for the treatment of adults diagnosed with ADHD. 
The flexible dosing more closely parallels clinical practice 
than fixed dosing and consequently provides additional 
clinically relevant findings. Adverse events seldom lead to 
discontinuation of study medication and overall there was 
a very low discontinuation rate. The adverse events most 
frequently reported by patients included headache, decreased 
appetite, and insomnia. Adverse events were rarely serious. 
There were small increases in systolic and diastolic blood 
pressure and pulse.
The safety findings are comparable to other open-label 
studies of OROS methylphenidate in the treatment of 
ADHD in adults, although previous studies treated a smaller 
number of patients. Biederman and colleagues reported a 
six-week study in 36 adults with late-onset ADHD, Fallu 
and colleagues treated 30 adults with ADHD for 38 days, 
and Ramos-Quiroga and colleagues treated 70 adults 
with ADHD for 90 days, and all studies observed that the 
medication was well tolerated.28–30 With a much larger sample 
of 370 patients, the open-label findings reported herein 
significantly enhances our confidence that prolonged-release 
OROS methylphenidate is a well tolerated therapy for the 
treatment of adults with ADHD.
The seven-week open-label safety findings were gener-
ally consistent with the five-week fixed-dose double-blind 
phase of the trial.23 The small increases in systolic and 
diastolic blood pressure and pulse during the open-label 
phase were comparable to the double-blind phase. Medi-
cations used to treat ADHD including methylphenidate 
compounds are associated with small increases on heart 
rate and blood pressure, but the changes are usually modest 
with no clinically significant changes.13,14 As discussed 
in guidelines for the use of these medications for the 
treatment of ADHD in children and adults, the potential 
cardiovascular effects are generally considered acceptable 
and manageable and can be monitored as the physician feels 
necessary.9,31 As well, all drug products for the treatment 
of ADHD provide patient medication guides to inform 
about possible cardiovascular effects associated with of 
the medication.15
As discussed by Godfrey and Rostain, when choosing 
a medication for treating adults with ADHD, important 
considerations are the control of symptoms throughout the 
working day with a regimen that may enhance adherence, and 
a formulation that can minimize the possible misuse of the 
medication.13,14 The osmotic controlled-release technology 
of the once-daily OROS methylphenidate formulation 
achieves a rapid onset of effect and delivers methylphenidate 
in a controlled manner for approximately 12 hours, thereby 
allowing extended coverage of symptoms during the day.19,32 
In addition, the physical properties of the OROS mechanism 
of delivery reduce the risk of possible methylphenidate 
substance abuse.33
In this open-label study, investigators adjusted the dose 
to optimize efficacy and tolerability for each patient based on 
their judgment of clinical response. The majority of patients 
(85%) received 36 mg, 54 mg, or 72 mg as their last daily 
dose; the 54 mg dose was most frequently administered as a 
last dose and maximum dose. For the three most frequently 
administered dosages, the incidence of adverse events 
decreased over time, suggesting that investigators were 
adjusting the dosage to optimize tolerability. However, 
this decrease may reflect, at least partially, longer exposure 
to the medication and increased tolerance in the patients. 
Along with the decrease in adverse events, patients 
continued to show improvements on the measure of efficacy 
(ie, decreases in CAARS total score) during the open-label 
phase. This result, along with the safety findings, suggests 
that investigators were able to optimize the daily dosage for 
a patient to achieve a balance between maintaining efficacy 
and minimizing adverse events.
There are a number of limitations associated with 
the reported study. The results covered a seven-week 
treatment period and did not provide information on the 
long-term safety of OROS methylphenidate treatment of 
ADHD in adults. Patients were not randomized which may 
limit the overall conclusions. Sample size was relatively 
large compared to other studies but not of the magnitude 
required to evaluate the possibility of rare adverse events. 
Patients with other Axis I disorder or patients with a high 
cardiovascular risk profile were excluded and there was 
limited ethnical/racial diversity. Concomitant psychotherapy 
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or other therapeutic options were not administered to 
improve the treatment effect.
In conclusion, the seven-week open-label results 
provided additional support for the safety and tolerability 
of prolonged-release OROS methylphenidate in a flexible 
dose regimen for the treatment of adults diagnosed with 
ADHD. Moreover, the findings provided further guidance 
for usual medical care for the treatment of ADHD in adults 
in that most patients have the optimal trade-off between 
efficacy and absence of side effects with dosages of 36, 54, 
or 72 mg/day.
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